Clinical Trials Logo

Clinical Trial Summary

Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients : a Prospective, Randomized Controlled, Open Label, Phase II Clinical Trial


Clinical Trial Description

Chidamideļ¼Œa novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China. The aim of this study was to observe the efficacy and safety of Chidamide With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide for Peripheral T Cell Lymphoma Patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03617432
Study type Interventional
Source Peking University
Contact Jun Zhu, Dr.
Phone 010-88140650
Email dreaming2217@hotmai.com
Status Recruiting
Phase Phase 2
Start date August 28, 2018
Completion date September 30, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03611231 - Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma Phase 2
Not yet recruiting NCT03494634 - Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors Phase 2